What are the top 10 corporate VCs in biopharma today? And what do they want to fund — or steer clear of?
Corporate money from Big Pharma is bleeding into private equity deals at a rapid clip, now representing a huge chunk of the total cash pie doled out to biotech ventures each year. Their motivations have moved beyond stocking research-starved pipelines, instead moving into private finance because the ideas they stumble on can influence longterm strategy.
Plus, well… they could use the returns.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.